tbuckley/cabot-search huggingface dataset:
FRI0643 Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis
Authors: J. S. Dekkers, S. A. Bergstra, A. Chopra, M. Tikly, J. E. Fonseca, K. Salomon-Escoto, T. Huizinga, D. van der Woude
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> In rheumatoid arthritis (RA), the relationship between autoantibody status and treatment response to methotrexate remains unclear. As methotrexate is the most widely used anti-rheumatic drug in clinical practice, it would be important to know whether the presence of autoantibodies is associated with better treatment response, since patients may benefit from treatment tailored to "autoantibody status". <h3>Objectives:</h3> We investigated the relationship between autoantibody status and remission in newly diagnosed RA-patients treated with first-line methotrexate. <h3>Methods:</h3> RA-patients initially treated with methotrexate were selected from an international observational database (METEOR). Patients were stratified into autoantibody-positive (rheumatoid factor (RF)- and/or anti-citrullinated-protein antibodies (ACPA)-positive) or -negative (RF- and ACPA- negative). The effect of autoantibody status on the chance of achieving remission within 3 to 6 months was analysed using Cox-proportional hazards regression. <h3>Results:</h3> Data from 1826 RA-patients were available for analysis. DAS remission was achieved in 17% (318/1,826). This was similar in autoantibody-positive (17% (282/1629)) and -negative patients (18% (36/197)). Hence, autoantibody positivity was not associated with remission (HR0.89, 95%CI 0.57;1.38). Similar findings were found when stratified for methotrexate monotherapy (HR0.75, 95%CI 0.41;1.37) or combination treatment (HR0.76, 95%CI 0.37;1.54). Good physical function (HAQ&lt;0.5) was achieved in 33% (530/1590) of all patients. Autoantibody-positivity was also not associated with HAQ&lt;0.5 (HR1.05, 95%CI 0.71;1.57). <h3>Conclusions:</h3> In conclusion, we found that autoantibody status was not associated with early remission in newly diagnosed RA-patients receiving methotrexate in real-world clinical practice. These results do not support the hypothesis that treatment should be tailored to "autoantibody status" when it comes to initiating methotrexate therapy as first-line anti-rheumatic treatment. Rather, our results indicate that that methotrexate is effective as primary anchor drug regardless of autoantibody status. <h3>Disclosure of Interest:</h3> None declared
AB0720 Systemic sclerosis and cancer development. a single-centre experience
Authors: E. Pelechas, E. Kaltsonoudis, P.V. Voulgari, A.A. Drosos
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic Sclerosis (SSc) is an autoimmune connective tissue disease with multisystem involvement, and sometimes devastating results. In bibliography there are reports that scleroderma patients present a higher incidence of risk for cancer when compared with the general population. However, different estimates have been reported. <h3>Objectives</h3> The purpose of the present study was to evaluate the frequency of cancer development (CD) in a cohort of patients with SSc. <h3>Methods</h3> Patients that fulfilled the 2013 American College of Rheumatology/EUropean League Against Rheumatism criteria for SSc and were followed up since 1999, were included. Date of disease onset, disease duration, autoantibodies, age, pulmonary hypertension, comorbidities and the type of CD have all been taken into account, during the period 1991–2016. <h3>Results</h3> Seventy-nine SSc patients have been included. 46 with limited (lcSSc) and 33 with diffuse cutaneous Systemic Sclerosis (dcSSc). Six of them, (7.6%) developed different types of cancer. Most of them were adenocarcinomata. More specifically, 2 developed pulmonary adenocarcinoma (1 with lcSSc and 1 with dcSSc), 1 follicular carcinoma of the thyroid gland (lcSSc), 1 colorectal adenocarcinoma (lcSSc), 1 B-cell lymphoma (MALT lymphoma), and 1 prostate adenocarcinoma (dcSSc). Five out of six were female patients. Mean age at the time of cancer diagnosis was 66.8-years-old, while SSc has been diagnosed at the mean age of 49.4 years. Mean time of developing any type of cancer was 15.8 years after SSc diagnosis. The diagnosis of cancer was done the last 20 months. All patients were non-smokers, had gastro-oesophageal reflux disease and pulmonary fibrosis, while 4/6 had also pulmonary hypertension and were under treatment with phosphodiesterase 5 inhibitors and bosentan. Scleroderma patients with CD have been referred to the corresponding oncology clinic for further treatment. <h3>Conclusions</h3> The present study on SSc and CDE provides data showing a potential association between the two entities. We found a high frequency of cancer development in patients with SSc (7.6%). Thus, a careful monitoring and screening is required when physicians follow-up scleroderma patients. <h3>Disclosure of Interest</h3> None declared
Predictors of Overall Survival for Multiple Myeloma Patients Depending on Transplant Status According to a Retrospective, Non-Interventional Study in Norway
Authors: Fredrik H. Schjesvold, Anderson Jenna, Jaak Sõnajalg, Amy Leval, Anna Lysén, Saeeda Rana, Päivi Castren-Kortekangas, Fredrik Borgsten
Journal: Blood (2018)
FRI0064 Right ventricle diastolic dysfunction in early rheumatoid arthritis patients: risk factors and the effect of antirheumatic therapy
Authors: I.G. Kirillova, D. Novikova, T. Popkova, H. Udachkina, E. Markelova, A. Volkov, Y. Gorbunova
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To determine the frequency of diastolic dysfunction of the right ventricle (RVDD) in patients (pts) with early rheumatoid arthritis (RA) prior to therapy with basic anti-inflammatory drugs (DMARDs), examine its relationship with traditional risk factors of cardiovascular disease and markers of inflammation, to study the effect of antirheumatic therapy administered in accordance with "treat to target" (T2T) principles on RVDD in early RA pts during 18 month follow-up. <h3>Methods</h3> A total of 66 pts with early RA (ACR/EULAR criteria, 2010 were included: 71% of women, age 56<sup>46;61</sup> years, disease duration 6<sup>4;8</sup> months; DAS28 5.3 [5.0;6.2], positive for ACCP (100%)/RF (87%), without prior administration of DMARDs and glucocorticoides. All pts underwent blood pressure monitoring (BP), echocardiography, tissue Doppler imaging. Methotrexate (MT) therapy was started in all pts with an escalation of the dose up to 30 mg/week subcutaneously. In case of no remission 3 months later, MT was added with biologic therapy (BT): Adalimumab, Certolizumab pegol, Abatacept, Rituximab. After 18 months 29 (44%) pts achieved remission. Antihypertensive therapy was administered in 51 (77%) pts: ACE inhibitors, ARBs, beta-blockers, calcium antagonists, diuretics. <h3>Results</h3> At baseline RVDD was detected in 16 (24%) pts. RVDD related factors that remained associated on a multivariable forward stepwise linear regression analysis were body mass index (BMI) (β-coefficient (95% CI) 0,3 (-0,003;−0,008), SDAI 0,2 (-0,009;−0,001), carotid atherosclerosis (CA) 0,2 (-0,3;0,01), disease duration 0,2 (-0,02;0,001). Multiple coefficient of determination (R2) was 38% (p=0,03). After 18 months the incidence rate of RVDD decreased from 24% to 18%, p&gt;0.05. The dynamics of diastolic function was multidirectional. RVDD was normalised in 10 (63%) of 16 RA pts with RVDD (p=0.02). All of them had effective control of BP and achieved remission. 67% of pts with normalised RVDD received MT+BT. 5 (31%) pts with new cases of RVDD and 6 pts with preserved RVDD did not reach the target values of BP and RA remission. <h3>Conclusions</h3> Presens of CA, higher BMI, SDAI and disease duration strongly associated with the incidence rate of RVDD. A significant decrease of RVDD in case of achieved targeted BP values and RA remission was observed during 18 month therapy of early RA pts in accordance with "T2T" principles <h3>Disclosure of Interest</h3> None declared
Abstract 16602: Atorvastatin Alters Coronary Plaque Composition and Distribution of Plaque Changes on CTA: Plaque-based Analysis in a Randomized Controlled Trial of Atorvastatin in HIV
Authors: Borek Foldyna, Janet Lo, Steven Grinspoon, Udo Hoffmann, Michael Lu
Journal: Circulation (2016)

Introduction: Coronary CT angiography (CTA) demonstrates reduction in total non-calcified coronary plaque volume in HIV with statin treatment. However changes in coronary plaque composition as well...
Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib
Authors: Inhye E. Ahn, Xin Tian, Maher Albitar, Sarah E. M. Herman, Erika M. Cook, Susan Soto, Wanlong Ma, David Ipe, L. Claire Tsao, Mei Cheng, James P. Dean, Adrian Wiestner
Journal: Blood (2018)
Bacille Calmette–Guérin vaccination of healthcare personnel: changing epidemiology calls for new recommendations in Norway
Authors: Trude M. Arnesen, Arne B. Brantsæter, Hanne Nøkleby
Journal: European Respiratory Journal (2019)

Until 2018, bacille Calmette–Guérin (BCG) vaccination was strongly recommended for all unvaccinated personnel and students in the healthcare sector in Norway. From June 2018, only a select group of students and healthcare personnel have been targeted for BCG vaccination, i.e. previously unvaccinated healthcare workers and students under 35 years of age who are caring for adult patients with pulmonary tuberculosis (TB) in hospitals or involved with mycobacterial culture in laboratories. What was the rationale behind this policy change? Low risk of tuberculosis in Norway prompts abandoning a policy of universal BCG vaccination of all health students and personnel <http://ow.ly/2lYW30mIVRN>
More evidence for implant-based breast reconstruction
Authors: Nicola Rocco, Giuseppe Catanuto
Journal: The Lancet Oncology (2019)

The scarcity of randomised controlled trials is a key issue in surgical research. The dearth of trials results from several methodological challenges, and because of surgeons' reluctance to be involved in study design.1 Nonetheless, experimental research is crucial to the generation of high-quality data to assess the effects of new procedures or devices before introducing them into standard practice. This insufficiency of high-level evidence becomes a paradox when dealing with implant-based breast reconstruction.
IL-13 secreted by ILC2s promotes the self-renewal of intestinal stem cells through circular RNA circPan3
Authors: Pingping Zhu, Xiaoxiao Zhu, Jiayi Wu, Luyun He, Tiankun Lu, Yanying Wang, Benyu Liu, Buqing Ye, Lei Sun, Dongdong Fan, Jing Wang, Liuliu Yang, Xiwen Qin, Ying Du, Chong Li, Lei He, Weizheng Ren, Xin Wu, Yong Tian, Zusen Fan
Journal: Nature Immunology (2019)
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
Authors: Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Stephen Caldwell, Mitchell L. Shiffman, Charles Landis, Bertus Eksteen, Kosh Agarwal, Andrew Muir, Simon Rushbrook, Xiaomin Lu, Jun Xu, Jen‐Chieh Chuang, Andrew N. Billin, Georgia Li, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Christopher L. Bowlus, Kris V. Kowdley
Journal: Hepatology (2019)

Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double-blind, placebo-controlled study, we tested the safety and efficacy of cilofexor (formerly GS-9674), a nonsteroidal farnesoid X receptor agonist in patients without cirrhosis with large-duct PSC. Patients were randomized to receive cilofexor 100 mg (n = 22), 30 mg (n = 20), or placebo (n = 10) orally once daily for 12 weeks. All patients had serum alkaline phosphatase (ALP) > 1.67 × upper limit of normal and total bilirubin ≤ 2 mg/dL at baseline. Safety, tolerability, pharmacodynamic effects of cilofexor (serum C4 [7α-hydroxy-4-cholesten-3-one] and bile acids), and changes in liver biochemistry and serum fibrosis markers were evaluated. Overall, 52 patients were randomized (median age 43 years, 58% male, 60% with inflammatory bowel disease, 46% on ursodeoxycholic acid). Baseline median serum ALP and bilirubin were 348 U/L (interquartile range 288-439) and 0.7 mg/dL (0.5-1.0), respectively. Dose-dependent reductions in liver biochemistry were observed. At week 12, cilofexor 100 mg led to significant reductions in serum ALP (median reduction -21%; P = 0.029 versus placebo), gamma-glutamyl transferase (-30%; P < 0.001), alanine aminotransferase (ALT) (-49%; P = 0.009), and aspartate aminotransferase (-42%; P = 0.019). Cilofexor reduced serum C4 compared with placebo; reductions in bile acids were greatest with 100 mg. Relative reductions in ALP were similar between ursodeoxycholic acid-treated and untreated patients. At week 12, cilofexor-treated patients with a 25% or more relative reduction in ALP had greater reductions in serum alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, tissue inhibitor of metalloproteinase 1, C-reactive protein, and bile acids than nonresponders. Adverse events were similar between cilofexor and placebo-treated patients. Rates of grade 2 or 3 pruritus were 14% with 100 mg, 20% with 30 mg, and 40% with placebo. Conclusion: In this 12-week, randomized, placebo-controlled study, cilofexor was well tolerated and led to significant improvements in liver biochemistries and markers of cholestasis in patients with PSC.
AB0607 Clinical profile of filipino patients with systemic lupus erythematosus
Authors: A.-T.M. Santiago, M. Tee, C. Tee
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To determine the clinical profile of Filipino SLE patients as determined using the 2012 Systemic Lupus Collaborating Clinics (SLICC) criteria. <h3>Methods</h3> We checked which among the SLICC criteria were fulfilled by Filipino SLE patient when we examined them and their case records, as part of a nationwide genetic study on SLE conducted from October 2015 to March 2017. <h3>Results</h3> Two hundred twenty-five patients who were diagnosed to have SLE after 18 years of age were evaluated. The mean age of the population at the time of evaluation was 37.76 years. Females comprised 98% of our population. Mean age of onset was 30.68-year-old, while the mean age at diagnosis was 31.52-year-old. Acute cutaneous rash was found in 82%; arthritis 80%; non-scarring alopecia 65%; oral ulcers 52%; renal disorder 41%; chronic cutaneous rash in 28%; leukopenia 23%; hemolytic anaemia 17%; thrombocytopenia 16%; serositis 13%; and neurologic disorder 6%. Anti-nuclear antibody was present in 88%; low complement 33%; antidsDNA in 29%; direct Coombs' 4%; antiphospholipid antibody 2%; and anti-Smith antibody in 2%. Kidney biopsy was performed in only 6% (15/225) of patients, 33% of whom had Class IV histopathologic results. <h3>Conclusions</h3> Filipino SLE patients typically present with acute cutaneous rash, arthritis, nonscarring alopecia and oral sores. Renal disorder, hematologic and neurologic manifestations are found to be less common among them. Finally, it was noted that renal biopsy is not commonly performed among these patients. <h3>Disclosure of Interest</h3> None declared
Opioid Prescribing Rates in Nonmetropolitan and Metropolitan Counties Among Primary Care Providers Using an Electronic Health Record System — United States, 2014–2017
Authors: Macarena C. García, Charles M. Heilig, Scott H. Lee, Mark Faul, Gery Guy, Michael F. Iademarco, Katherine Hempstead, Dorrie Raymond, Josh Gray
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Drug overdose is the leading cause of unintentional injury-associated death in the United States. Among 70,237 fatal drug overdoses in 2017, prescription opioids were involved in 17,029 (24.2%) (1). Higher rates of opioid-related deaths have been recorded in nonmetropolitan (rural) areas (2). In 2017, 14 rural counties were among the 15 counties with the highest opioid prescribing rates.* Higher opioid prescribing rates put patients at risk for addiction and overdose (3). Using deidentified data from the Athenahealth electronic health record (EHR) system, opioid prescribing rates among 31,422 primary care providers† in the United States were analyzed to evaluate trends from January 2014 to March 2017. This analysis assessed how prescribing practices varied among six urban-rural classification categories of counties, before and after the March 2016 release of CDC's Guideline for Prescribing Opioids for Chronic Pain (Guideline) (4). Patients in noncore (the most rural) counties had an 87% higher chance of receiving an opioid prescription compared with persons in large central metropolitan counties during the study period. Across all six county groups, the odds of receiving an opioid prescription decreased significantly after March 2016. This decrease followed a flat trend during the preceding period in micropolitan and large central metropolitan county groups; in contrast, the decrease continued previous downward trends in the other four county groups. Data from EHRs can effectively supplement traditional surveillance methods for monitoring trends in opioid prescribing and other areas of public health importance, with minimal lag time under ideal conditions. As less densely populated areas appear to indicate both substantial progress in decreasing opioid prescribing and ongoing need for reduction, community health care practices and intervention programs must continue to be tailored to community characteristics.
BZLF1-DEC205 Fusion Protein Enhances EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease
Authors: Elshafa Hassan Ahmed, Eric Brooks, Shelby Sloan, Sarah Schlotter, Frankie Jeney, Charlene Mao, Polina Shindiapina, Salma Shire, Claire Hale, Manjusri Das, Alexander Prouty, Michael A. Caligiuri, Robert A Baiocchi
Journal: Blood (2018)
AB0281 Reduction rate of rheumatoid factor reflects disease activity of rheumatoid arthritis
Authors: N. Okumura, T. Kawasaki, T. Yayama, K. Kumagai, S. Imai
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid factor (RF) is involved in the pathology of rheumatoid arthritis (RA) and its titer varies during the course of treatment with biological or synthetic DMARD. <h3>Objectives</h3> In this study, we examined the relationship between RF change rate and disease activity. <h3>Methods</h3> We analysed 287 RA patients (mean age 62.3 years; mean disease duration 13.1 years) in our hospital between 2015 and 2017, who were able to confirm the RF, and 3 groups were classified according to the change rate of RF for 1 year (92 in decreasing less than 80%, 114 in unchanged 80% or more, less than 120% and 81 in increasing 120% or more). We evaluated disease activity by simplified disease activity index(SDAI). <h3>Results</h3> The drugs used are: MTX usage rate 63.1%, mean amount 3.81 mg, PSL usage rate 37.3%, mean amount 1.47 mg, biological drugs usage rate 48.8%. Disease activity change amount in 1 year (delta SDAI) was −0.88 (from 6.90 to 6.02). The median RF titer at baseline was 76 (27.5–178.5), the median RF change rate was 96% (71.5–125) and delta SDAI was significantly improved in the decreasing group (−1.97, 0.005,–0.04, p=0.0011). The swollen joint counts, tender joint counts, global assessment of evaluator and CRP were similarly improved significantly in this group. <h3>Conclusions</h3> Although RF dose not decrease in all cases, it suggested that reduction rate of RF reflects disease activity. <h3>Disclosure of Interest</h3> None declared
Flexural Hyperpigmentation With Reticulation in an Adolescent Girl
Authors: Anuradha Bishnoi, Nirmalya Banerjee, Davinder Parsad
Journal: JAMA Dermatology (2019)

An adolescent girl with polycystic ovarian syndrome presented with hyperpigmented skin lesions on her neck, upper limbs, and trunk, which had begun 6 months previously as recurrent pruritic erythematous papules that subsided leaving brownish-bluish black hyperpigmentation. What is your diagnosis?
Safe and Effective Use of Rivaroxaban for Treatment of Cancer Associated Venous Thromboembolic Disease
Authors: Gerald A. Soff, Debra M. M Sarasohn, Eva S Haegler-Laube, Sean M Devlin, Yimei Miao, Gemma Bendheim, Jeanette Batista, Jonathan Wills, Jodi V Mones, Cy Wilkins, Simon H Mantha
Journal: Blood (2018)
Abstract 15394: Prognostic Value of Calculated Plasma Volume Status in Patients Admitted for Acute Decompensated Heart Failure With Reduced or Preserved Left Ventricular Ejection Fraction: A Prospective Study
Authors: Shunsuke Tamaki, Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Yusuke Iwasaki, Masato Kawasaki, Atsushi Kikuchi, Tsutomu Kawai, Masahiro Seo, Iyo Ikeda, Eiji Fukuhara, Makoto Abe, Jun Nakamura, Kiyomi Kayama, Masatsugu Kawahira, Kazuya Tanabe, Masatake Fukunami
Journal: Circulation (2017)

Background: Plasma volume (PV) expansion plays an essential role in heart failure (HF). Recently, it has been reported that PV can be estimated by a simple formula based on hematocrit and body weig...
Cell-Type-Specific Responses to Interleukin-1 Control Microbial Invasion and Tumor-Elicited Inflammation in Colorectal Cancer
Authors: Oxana Dmitrieva-Posocco, Amiran Dzutsev, David F. Posocco, Vivianty Hou, Wuxing Yuan, Vishal Thovarai, Ilgiz A. Mufazalov, Matthias Gunzer, Igor P. Shilovskiy, Musa R. Khaitov, Giorgio Trinchieri, Ari Waisman, Sergei I. Grivennikov
Journal: Immunity (2019)
Cancer screening in the United States, 2012
Authors: Robert A. Smith, Vilma Cokkinides, Otis W. Brawley
Journal: CA A Cancer Journal for Clinicians (2012)

Abstract Each year the American Cancer Society (ACS) publishes a summary of its recommendations for early cancer detection, a report on data and trends in cancer screening rates, and select issues related to cancer screening. In this issue of the journal, current ACS cancer screening guidelines are summarized, as are the latest data on the use of cancer screening from the National Health Interview Survey. CA Cancer J Clin 2012. © 2012 American Cancer Society.
Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia
Authors: V. Alfonso, L. Iaccarino, T. Ottone, L. Cicconi, S. Lavorgna, M. Divona, R. Cairoli, A. Cristiano, C. Ciardi, S. Travaglini, G. Falconi, S. K. Hasan, A. Venditti, W. Arcese, M. T. Voso, F. Lo-Coco
Journal: Leukemia (2019)